Amgen completed the acquisition of Horizon Therapeutics for $27.8 billion, adding first-in-class, early-in-lifecycle medicines for rare diseases, including TEPEZZA, KRYSTEXXA and UPLIZNA, to Amgen's portfolio.

Amgen is increasingly focusing its R&D efforts on human genetics to enhance the likelihood of success, leveraging its biologic expertise and cutting-edge science and technology to study biological mechanisms.

Amgen continues to expand its global presence through its own affiliates, acquisitions and collaborations with third parties, including Astellas, BeiGene, Takeda and Kyowa Kirin, to deliver medicines to more patients.

Amgen is evaluating Horizon's supply chains and pursuing activities to further improve resiliency and efficiency, while also working to integrate Horizon's operations into Amgen's existing infrastructure.

Amgen is embedding environmental sustainability into the design, development and execution of new facilities, including on-site photovoltaic renewable energy generation and reduced carbon, waste and water footprints.

Amgen remains focused on pricing its products responsibly and delivering breakthrough treatments for unmet medical needs, while also working with the healthcare community to ensure continued innovation and patient access to needed medicines.

Amgen's sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, the company's profitability. The Inflation Reduction Act will introduce mandatory price setting in Medicare.

Amgen faces substantial competition from biosimilars and generics, which could impact the pricing and market share of its products. The company expects to face increasing competition from biosimilars and generics in the future.

Amgen's information technology systems, cyberattacks and information security breaches could significantly compromise the confidentiality, integrity and availability of its data, interrupt operations and/or affect its reputation.

Amgen is actively involved in the development of its own biosimilar products, which are competing against branded and biosimilar versions of competitors' products. In 2023, Amgen launched AMJEVITA and BEKEMV, and received FDA approval for Wezlana.

Amgen faces competition in various therapeutic areas, with other companies pursuing products or treatments for the same disease areas. This competition could impact the pricing and market share of Amgen's products.

Amgen is pursuing innovation efforts to strengthen its competitive position, including expanding disease areas, finding new methods of delivery and manufacture, and focusing on safety, efficacy, reliability, availability, patient convenience, price and reimbursement.

Amgen is using next-generation biomanufacturing plants with innovative technologies to optimize its manufacturing network, mitigate risks, and ensure adequate supply of products. These plants feature portable equipment and smaller footprints.

Amgen uses third-party contract manufacturers to supplement the capacity or capability of its commercial manufacturing network and to support its clinical trials. The company monitors the financial condition of its larger customers and limits its credit exposure.

Amgen is evaluating Horizon's supply chains and pursuing activities to further improve resiliency and efficiency. The company also uses a risk mitigation strategy that includes multiple sources or backup inventory of critical raw materials.

Amgen focuses its R&D on novel human therapeutics for the treatment of serious illnesses, capitalizing on its strengths in human genetics, novel biology and protein engineering, and leveraging cutting-edge science and technology.

Amgen is increasingly focusing its efforts on human genetics to enhance the likelihood of success and is applying artificial intelligence to its R&D activities, including to advance its human data efforts and its generative biology platform.

Amgen is conducting clinical trials for various product candidates, including tarlatamab, LUMAKRAS/LUMYKRAS, and TEZSPIRE, and is working to mitigate effects of health-related events on clinical trial activities.

Amgen issued $24 billion of senior notes and borrowed $4 billion under a term loan credit agreement to finance the acquisition of Horizon Therapeutics.

Amgen intends to continue to return capital to stockholders through the payment of cash dividends and stock repurchases. The company increased its quarterly cash dividend by 10% in 2023 and by 6% in 2024.

Amgen is focused on strategic investments in both internal and external R&D, including acquisitions and licensing activities, to enhance its position within the industry and diversify its product pipeline.

Amgen has set long-term environmental targets to achieve by 2027, including carbon neutrality, reducing water consumption by 40% and reducing waste disposed by 75%. The company also issued its first green bonds in 2022.

Amgen believes that a diverse and inclusive culture fosters innovation and supports its ability to serve patients. The company has a Diversity, Inclusion and Belonging Council and Employee Resource Groups to promote these initiatives.

Amgen's staff are guided by the company's Code of Conduct, which is designed to help every person who does business on the company's behalf understand what is expected of them.

Uncertain macroeconomic conditions, including higher inflation, rising interest rates and instability in the financial system, as well as rising healthcare costs continue to pose challenges to Amgen's business.

Policy makers in both the major U.S. political parties have supported policies to lower drug costs, and the IRA includes provisions requiring mandatory price setting in Medicare for certain drugs beginning in 2026.

The EU is undergoing a review and possible revision of its pharmaceutical legislation, which, if implemented, will likely have a significant impact on the landscape for access and pricing decisions within Member States.